[January 04, 2017] |
|
OSE Immunotherapeutics to Present at Biotech Showcase™ 2017 Conference
Regulatory News:
OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo:
OSE), today announced that Dominique Costantini, CEO, will present an
overview of the Company's business and will be available to participate
in one-on-one meetings with investors at the Biotech Showcase™ 2017 to
be held January 9-11, 2017, in San Francisco, CA (News - Alert).
The details of OSE Immunotherapeutics' presentation are as follows:
Event: Biotech Showcase 2017 Conference
Date: Tuesday, January 10, 2017
Time: 10:00am (PT) / 1:00pm (ET)
Location: Room 3 (Ballroom level), Hilton San Francisco Union
Square - 333 O'Farrell Street
The presentation will be webcast live and remain available for 3 months
thereafter on https://event.webcasts.com/starthere.jsp?ei=1130361.
ABOUT BIOTECH SHOWCASE Biotech Showcase™ is an investor and
partnering conference devoted to providing private and public
biotechnology and life sciences companies with an opportunity to present
to, and meet with, investors and pharmaceutical executives in one place
during the course of one of the industry's largest annual healthcare
investor conferences. Investors and biopharmaceutical executives from
around the world gather in San Francisco during this critical week which
is widely viewed as setting the tone for the coming year.
ABOUT OSE IMMUNOTHERAPEUTICS Our ambition is to become
a world leader in activation and regulation immunotherapies OSE
Immunotherapeutics is a biotechnology company focused on the development
of innovative immunotherapies for immune activation and regulation in
the fields of immuno-oncology, auto-immune diseases and transplantation. The
company has a balanced portfolio of first-in-class products with a
diversified risk profile ranging from clinical phase 3 registration
trials to R&D:
In immuno-oncology:
-
Tedopi®, a combination of 10 optimized neo-epitopes to induce
specific T activation in immuno-oncology - Currently in
registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan
Status in the US - Registration expected in 202 - a Phase 2 with
Tedopi® in combination with a checkpoint inhibitor in NSCLC is
considered in 2017.
-
Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-a
receptor - In preclinical development for several cancer models.
In auto-immune diseases and transplantation:
-
FR104, CD28-antagonist in immunotherapy - Phase 1 trial
completed - For the treatment of autoimmune diseases
and for use with transplantation - Licensed to Janssen Biotech Inc.
to pursue clinical development.
-
Effi-7, interleukin receptor-7 antagonist - In preclinical
development for inflammatory bowel diseases and other
autoimmune diseases. License option agreement with
Servier for the development and commercialization.
The portfolio's blockbuster potential gives OSE Immunotherapeutics the
ability to enter global agreements at different stages of development
with major pharmaceutical players.
Immunotherapy is a highly promising and growing market. By 2023
Immunotherapy of cancer could represent nearly 60% of treatments against
less than 3% at present * and the projected market is estimated at $67
billion in 2018 **.
There are more than 80 autoimmune diseases that represent a significant
market including major players in the pharmaceutical industry with sales
towards $10 billion for the main products. The medical need is largely
unmet and requires the provision of new innovative products involved in
the regulation of the immune system.
*Citi Research Equity **BCC (News - Alert) Research
More information: http://ose-immuno.com
Click and follow us on Twitter
and Linkedln
Forward-looking statements This press release
contains express or implied information and statements that might be
deemed forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based
upon certain assumptions and assessments made by OSE Immunotherapeutics'
management in light of its experience and its perception of historical
trends, current economic and industry conditions, expected future
developments and other factors they believe to be appropriate. These
forward-looking statements include statements typically using
conditional and containing verbs such as "expect", "anticipate",
"believe", "target", "plan", or "estimate", their declensions and
conjugations and words of similar import. Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE Immunotherapeutics'
shareholders and other investors are cautioned that the completion of
such expectations is by nature subject to various risks, known or not,
and uncertainties which are difficult to predict and generally beyond
the control of OSE Immunotherapeutics. These risks could cause actual
results and developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by OSE
Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance. This press release includes only
summary information and should be read with the OSE Immunotherapeutics
Reference Document filed with the AMF on 8 June 2016 under the number
R.16-052, the consolidated financial statements and the management
report for the fiscal year 2015, as well as the Merger Document
registered with the AMF on 26 April 2016 under number E.16-026, all
available on the OSE Immunotherapeutics' website. Other than as
required by applicable law, OSE Immunotherapeutics issues this press
release at the date hereof and does not undertake any obligation to
update or revise the forward-looking information or statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005697/en/
[ Back To TMCnet.com's Homepage ]
|